|
1
|
Bleeker FE, Molenaar RJ and Leenstra S:
Recent advances in the molecular understanding of glioblastoma. J
Neurooncol. 108:11–27. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Van Meir EG, Hadjipanayis CG, Norden AD,
Shu HK, Wen PY and Olson JJ: Exciting new advances in
neuro-oncology: The avenue to a cure for malignant glioma. CA
Cancer J Clin. 60:166–193. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Newlands ES, O'Reilly SM, Glaser MG, Bower
M, Evans H, Brock C, Brampton MH, Colquhoun I, Lewis P,
Rice-Edwards JM, et al: The Charing Cross Hospital experience with
temozolomide in patients with gliomas. Eur J Cancer. 32A:2236–2241.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: European Organisation for Research and Treatment of
Cancer Brain Tumor and Radiotherapy Groups; National Cancer
Institute of Canada Clinical Trials Group: Radiotherapy plus
concomitant and adjuvant temozolomide for glioblastoma. N Engl J
Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang J, Stevens MF, Laughton CA,
Madhusudan S and Bradshaw TD: Acquired resistance to temozolomide
in glioma cell lines: Molecular mechanisms and potential
translational applications. Oncology. 78:103–114. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
D'Atri S, Tentori L, Lacal PM, Graziani G,
Pagani E, Benincasa E, Zambruno G, Bonmassar E and Jiricny J:
Involvement of the mismatch repair system in temozolomide-induced
apoptosis. Mol Pharmacol. 54:334–341. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lu C and Shervington A: Chemoresistance in
gliomas. Mol Cell Biochem. 312:71–80. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hall DA, Ptacek J and Snyder M: Protein
microarray technology. Mech Ageing Dev. 128:161–167. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sørensen MD, Fosmark S, Hellwege S, Beier
D, Kristensen BW and Beier CP: Chemoresistance and chemotherapy
targeting stem-like cells in malignant glioma. Adv Exp Med Biol.
853:111–138. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Izumiya M, Kabashima A, Higuchi H,
Igarashi T, Sakai G, Iizuka H, Nakamura S, Adachi M, Hamamoto Y,
Funakoshi S, et al: Chemoresistance is associated with cancer stem
cell-like properties and epithelial-to-mesenchymal transition in
pancreatic cancer cells. Anticancer Res. 32:3847–3853.
2012.PubMed/NCBI
|
|
11
|
von Manstein V, Yang CM, Richter D, Delis
N, Vafaizadeh V and Groner B: Resistance of cancer cells to
targeted therapies through the activation of compensating signaling
loops. Curr Signal Transduct Ther. 8:193–202. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Spiegl-Kreinecker S, Buchroithner J,
Elbling L, Steiner E, Wurm G, Bodenteich A, Fischer J, Micksche M
and Berger W: Expression and functional activity of the
ABC-transporter proteins P-glycoprotein and multidrug-resistance
protein 1 in human brain tumor cells and astrocytes. J Neurooncol.
57:27–36. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cui Y, Lin J, Zuo J, Zhang L, Dong Y, Hu
G, Luo C, Chen J and Lu Y: AKT2-knockdown suppressed viability with
enhanced apoptosis, and attenuated chemoresistance to temozolomide
of human glioblastoma cells in vitro and in vivo. Onco Targets
Ther. 8:1681–1690. 2015.PubMed/NCBI
|
|
14
|
Zhang J, Stevens MF and Bradshaw TD:
Temozolomide: Mechanisms of action, repair and resistance. Curr Mol
Pharmacol. 5:102–114. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bobola MS, Kolstoe DD, Blank A,
Chamberlain MC and Silber JR: Repair of 3-methyladenine and abasic
sites by base excision repair mediates glioblastoma resistance to
temozolomide. Front Oncol. 2:1762012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fu D, Calvo JA and Samson LD: Balancing
repair and tolerance of DNA damage caused by alkylating agents. Nat
Rev Cancer. 12:104–120. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Happold C, Roth P, Wick W, Schmidt N,
Florea AM, Silginer M, Reifenberger G and Weller M: Distinct
molecular mechanisms of acquired resistance to temozolomide in
glioblastoma cells. J Neurochem. 122:444–455. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wertz IE, Kusam S, Lam C, Okamoto T,
Sandoval W, Anderson DJ, Helgason E, Ernst JA, Eby M, Liu J, et al:
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1
and FBW7. Nature. 471:110–114. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kanzawa T, Germano IM, Komata T, Ito H,
Kondo Y and Kondo S: Role of autophagy in temozolomide-induced
cytotoxicity for malignant glioma cells. Cell Death Differ.
11:448–457. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lin C-J, Lee C-C, Shih YL, Lin CH, Wang
SH, Chen TH and Shih CM: Inhibition of mitochondria- and
endoplasmic reticulum stress-mediated autophagy augments
temozolomide-induced apoptosis in glioma cells. PLoS One.
7:e387062012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kogias E, Osterberg N, Baumer B, Psarras
N, Koentges C, Papazoglou A, Saavedra JE, Keefer LK and Weyerbrock
A: Growth-inhibitory and chemosensitizing effects of the
glutathione-S-transferase-π-activated nitric oxide donor PABA/NO in
malignant gliomas. Int J Cancer. 130:1184–1194. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu G, Yuan X, Zeng Z, Tunici P, Ng H,
Abdulkadir IR, Lu L, Irvin D, Black KL and Yu JS: Analysis of gene
expression and chemoresistance of CD133+ cancer stem
cells in glioblastoma. Mol Cancer. 5:672006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Takuro H, Kazuhide A and Yuichi H: The Cdk
inhibitor flavopiridol enhances temozolomide-induced cytotoxicity
in human glioma cells. J Neurooncol. 115:169–178. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hirose Y, Katayama M, Mirzoeva OK, Berger
MS and Pieper RO: Akt activation suppresses Chk2-mediated,
methylating agent-induced G2 arrest and protects from
temozolomide-induced mitotic catastrophe and cellular senescence.
Cancer Res. 65:4861–4869. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ye F, Zhang Y, Liu Y, Yamada K, Tso JL,
Menjivar JC, Tian JY, Yong WH, Schaue D, Mischel PS, et al:
Protective properties of radio-chemoresistant glioblastoma stem
cell clones are associated with metabolic adaptation to reduced
glucose dependence. PLoS One. 8:e803972013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen Y-S, Wu M-J, Huang C-Y, Lin SC,
Chuang TH, Yu CC and Lo JF: CD133/Src axis mediates tumor
initiating property and epithelial-mesenchymal transition of head
and neck cancer. PLoS One. 6:e280532011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu X, Madhankumar AB, Slagle-Webb B,
Sheehan JM, Surguladze N and Connor JR: Heavy chain ferritin siRNA
delivered by cationic liposomes increases sensitivity of cancer
cells to chemotherapeutic agents. Cancer Res. 71:2240–2249. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Isvoran A, Louet M, Vladoiu DL, Craciun D,
Loriot MA, Villoutreix BO and Miteva MA: Pharmacogenomics of the
cytochrome P450 2C family: Impacts of amino acid variations on drug
metabolism. Drug Discov Today. 22:366–376. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pacaud R, Cheray M, Nadaradjane A,
Vallette FM and Cartron PF: Histone H3 phosphorylation in GBM: A
new rational to guide the use of kinase inhibitors in anti-GBM
therapy. Theranostics. 5:12–22. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Borges KS, Castro-Gamero AM, Moreno DA, da
Silva Silveira V, Brassesco MS, de Paula Queiroz RG, de Oliveira
HF, Carlotti CG Jr, Scrideli CA and Tone LG: Inhibition of Aurora
kinases enhances chemosensitivity to temozolomide and causes
radiosensitization in glioblastoma cells. J Cancer Res Clin Oncol.
138:405–414. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tentori L, Ricci-Vitiani L, Muzi A,
Ciccarone F, Pelacchi F, Calabrese R, Runci D, Pallini R, Caiafa P
and Graziani G: Pharmacological inhibition of poly(ADP-ribose)
polymerase-1 modulates resistance of human glioblastoma stem cells
to temozolomide. BMC Cancer. 14:1512014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tang TK, Chiu SC, Lin CW, Su MJ and Liao
MH: Induction of survivin inhibition, G2/M cell cycle arrest and
autophagic on cell death in human malignant glioblastoma cells.
Chin J Physiol. 58:95–103. 2015.PubMed/NCBI
|
|
33
|
Zhao Z, Liu Y, He H, Chen X, Chen J and Lu
YC: Candidate genes influencing sensitivity and resistance of human
glioblastoma to Semustine. Brain Res Bull. 86:189–194. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Eich M, Roos WP, Nikolova T and Kaina B:
Contribution of ATM and ATR to the resistance of glioblastoma and
malignant melanoma cells to the methylating anticancer drug
temozolomide. Mol Cancer Ther. 12:2529–2540. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Munoz JL, Rodriguez-Cruz V, Greco SJ,
Nagula V, Scotto KW and Rameshwar P: Temozolomide induces the
production of epidermal growth factor to regulate MDR1 expression
in glioblastoma cells. Mol Cancer Ther. 13:2399–2411. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Popescu AM, Alexandru O, Brindusa C,
Purcaru SO, Tache DE, Tataranu LG, Taisescu C and Dricu A:
Targeting the VEGF and PDGF signaling pathway in glioblastoma
treatment. Int J Clin Exp Pathol. 8:7825–7837. 2015.PubMed/NCBI
|
|
37
|
Auger N, Thillet J, Wanherdrick K, Idbaih
A, Legrier ME, Dutrillaux B, Sanson M and Poupon MF: Genetic
alterations associated with acquired temozolomide resistance in
SNB-19, a human glioma cell line. Mol Cancer Ther. 5:2182–2192.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Han X, Zhang W, Yang X, Wheeler CG,
Langford CP, Wu L, Filippova N, Friedman GK, Ding Q,
Fathallah-Shaykh HM, et al: The role of Src family kinases in
growth and migration of glioma stem cells. Int J Oncol. 45:302–310.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Choi YL, Bocanegra M, Kwon MJ, Shin YK,
Nam SJ, Yang JH, Kao J, Godwin AK and Pollack JR: LYN is a mediator
of epithelial-mesenchymal transition and a target of dasatinib in
breast cancer. Cancer Res. 70:2296–2306. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Boivin D, Labbé D, Fontaine N, Lamy S,
Beaulieu E, Gingras D and Béliveau R: The stem cell marker CD133
(prominin-1) is phosphorylated on cytoplasmic tyrosine-828 and
tyrosine-852 by Src and Fyn tyrosine kinases. Biochemistry.
48:3998–4007. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li XY, Jiang LJ, Chen L, Ding ML, Guo HZ,
Zhang W, Zhang HX, Ma XD, Liu XZ, Xi XD, et al: RIG-I modulates
Src-mediated AKT activation to restrain leukemic stemness. Mol
Cell. 53:407–419. 2014. View Article : Google Scholar : PubMed/NCBI
|
